Atezolizumab

A randomized phase 3 trial designed to evaluate tiragolumab plus atezolizumab for certain patients with advanced lung cancer failed to meet its co-primary endpoint of PFS, topline data showed.

Atezolizumab administered before and during chemoradiation appeared safe and demonstrated immune-modulating activity among women with node-positive locally advanced cervical cancer, according to study results.

The FDA expanded the approval of atezolizumab to include adjuvant treatment of certain patients with non-small cell lung cancer.

In this video, Pasi A. Jänne, MD, PhD, director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and professor of medicine at Harvard Medical School, discusses results from the IMpower010 study presented at ESMO 2021.

Patients with early-stage non-small cell lung cancer who received best supportive care vs. atezolizumab after adjuvant chemotherapy had a higher relapse rate, but relapse patterns appeared similar between the groups, study results showed.

Use of atezolizumab as part of neoadjuvant therapy and again as maintenance met predetermined safety criteria for patients with resectable pleural mesothelioma, according to study results.

The combination of atezolizumab, carboplatin and pemetrexed demonstrated encouraging activity among patients with nonsquamous non-small cell lung cancer and untreated, asymptomatic brain metastases, according to phase 2 study results.

Adjuvant atezolizumab improved DFS among patients with non-small cell lung cancer with nodal involvement, according to study results.

Genentech has decided to voluntarily withdraw its accelerated approval of atezolizumab plus nab-paclitaxel for treatment of PD-L1-positive, unresectable locally advanced or metastatic triple-negative breast cancer.

Recent data revealed the Right to Try track did not more successfully help oncologists obtain investigational drugs than Expanded Access, which has an extra step of receiving FDA authorization for each patient.